The effect and mechanism of erianin on the reversal of oxaliplatin resistance in human colon cancer cells

Su, Chang; Liu, Shaoqun; Ma, Xiaoying; Liu, Jiajun; Liu, Jianwen; Lei, Ming; Cao, Yiou

doi:10.1002/cbin.11684

Cited by 15 publications

(10 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Growth of colon cancer cells is suppressed when DNA binding of activated STAT3 is prevented [292]. C. Pyrimethamine in glioblastoma: Of great interest for potential use in treating glioblastoma or brain metastases from breast or lung cancer is the unusual property of pyrimethamine in being concentrated in the brain at several times greater levels than in plasma [293,294]. Pyrimethamine is synergistically cytotoxic with temozolomidethe mainstay in current glioblastoma treatment-in melanoma and pituitary adenoma cell lines [295,296].…”

Section: Pyrimethaminementioning

confidence: 99%

MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen

Kast¹,

Alfieri

Assi

et al. 2022

Cancers

View full text Add to dashboard Cite

In part one of this two-part paper, we present eight principles that we believe must be considered for more effective treatment of the currently incurable cancers. These are addressed by multidrug adjunctive cancer treatment (MDACT), which uses multiple repurposed non-oncology drugs, not primarily to kill malignant cells, but rather to reduce the malignant cells’ growth drives. Previous multidrug regimens have used MDACT principles, e.g., the CUSP9v3 glioblastoma treatment. MDACT is an amalgam of (1) the principle that to be effective in stopping a chain of events leading to an undesired outcome, one must break more than one link; (2) the principle of Palmer et al. of achieving fractional cancer cell killing via multiple drugs with independent mechanisms of action; (3) the principle of shaping versus decisive operations, both being required for successful cancer treatment; (4) an idea adapted from Chow et al., of using multiple cytotoxic medicines at low doses; (5) the idea behind CUSP9v3, using many non-oncology CNS-penetrant drugs from general medical practice, repurposed to block tumor survival paths; (6) the concept from chess that every move creates weaknesses and strengths; (7) the principle of mass—by adding force to a given effort, the chances of achieving the goal increase; and (8) the principle of blocking parallel signaling pathways. Part two gives an example MDACT regimen, gMDACT, which uses six repurposed drugs—celecoxib, dapsone, disulfiram, itraconazole, pyrimethamine, and telmisartan—to interfere with growth-driving elements common to cholangiocarcinoma, colon adenocarcinoma, glioblastoma, and non-small-cell lung cancer. gMDACT is another example of—not a replacement for—previous multidrug regimens already in clinical use, such as CUSP9v3. MDACT regimens are designed as adjuvants to be used with cytotoxic drugs.

show abstract

Section: Pyrimethaminementioning

confidence: 99%

MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen

Kast¹,

Alfieri

Assi

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Chemotherapy is still one of the most important treatment methods for patients with advanced gastric cancer. , Oxaliplatin and other drugs can effectively kill cancer cells and prolong the survival time of patients, which are the first-line drugs for the treatment of gastric cancer. , Although oxaliplatin has shown the advantages of definite efficacy in clinical practice, it still has the problem of drug resistance by reducing the effective concentration in cells through two pathways: reducing drugs into cancer cells or increasing efflux. , MRP1 and MRP2 are one of the main membrane proteins that transport oxaliplatin and are related to the occurrence of platinum drug resistance. , Combination therapy can enhance the efficacy of chemotherapeutic agents, reduce the dosage, minimize side effects, and even overcome tumor resistance, , but suitable combination drugs are lacking. Therefore, administration of multidrug resistance reversal agents or chemotherapy sensitizers is an effective means to solve this problem. − …”

Section: Introductionmentioning

confidence: 99%

“…Therefore, administration of multidrug resistance reversal agents or chemotherapy sensitizers is an effective means to solve this problem. 13 − 15 …”

Section: Introductionmentioning

confidence: 99%

Ultrasound-Assisted Extraction of Atractylodes chinensis (DC.) Koidz. Polysaccharides and the Synergistic Antigastric Cancer Effect in Combination with Oxaliplatin

Liang,

Wu,

Sun

et al. 2024

ACS Omega

View full text Add to dashboard Cite

Oxaliplatin (OXA) is recognized as a first-line drug for gastric cancer. However, low accumulation of the OXA in the target site and the development of drug resistance directly led to treatment failure. In the present study, an ultrasonic extraction method for Atractylodes chinensis (DC.) Koidz. polysaccharides (AKUs) and the combination treatment with OXA in vitro were studied. Results showed that when the pH level was 11, the ultrasound power at 450 W, the solid−liquid ratio was 1:20, and the ultrasound treatment for 30 min, the yield of AKUs was significantly increased to 13.20 ± 0.35%. The molecular weights of the AKUs ranged from 7.21 to 185.94 kDa, and its monosaccharides were mainly composed of arabinose (Ara), galactose (Gal), and glucose (Glu) with a ratio of 58.36, 16.90, and 15.49%, respectively. Cell experiments showed that, compared to OXA alone (2 μg/mL, inhibition rate of 18%), the treatment of OXA with AKUs had a significant synergistic inhibitory effect on MKN45 proliferation, which increased to 33, 41, and 45% with increasing AKUs concentrations (5−50 μg/mL), respectively, representing a 2.5-fold inhibition. Inductively coupled plasma-mass spectrometry (ICP-MS) determination confirmed that AKUs significantly increased the intracellular uptake of OXA by 29%, compared to that of OXA alone. We first demonstrated that the combined synergistic inhibitory effect of AKUs and OXA on gastric cancer cells was mediated by reducing the expression of efflux proteins (MRP1 and MRP2) and increasing the expression of ingested protein (OCT2). As a result of the above, AKUs deserved to be an effective adjuvant combined with chemotherapeutics in a clinical setting.

show abstract

“…12 In recent years, increasing studies have reported that Erianin has good anti-cancer activity in vitro and in vivo by blocking tumor cell cycle, inducing tumor cell apoptosis, activating tumor cell autophagy, inhibiting tumor cell migration, anti-tumor angiogenesis, and reversing multidrug resistance. [13][14][15] However, the impacts of Erianin on the stemness of CSCs are never been revealed.…”

Section: Introductionmentioning

confidence: 99%

“…Erianin is mainly extracted from Dendrobium and has been found to possess a wide range of pharmacological activities, including anti‐tumor, antibacterial, and anti‐inflammatory 12 . In recent years, increasing studies have reported that Erianin has good anti‐cancer activity in vitro and in vivo by blocking tumor cell cycle, inducing tumor cell apoptosis, activating tumor cell autophagy, inhibiting tumor cell migration, anti‐tumor angiogenesis, and reversing multidrug resistance 13–15 . However, the impacts of Erianin on the stemness of CSCs are never been revealed.…”

Section: Introductionmentioning

confidence: 99%

Erianin suppressed lung cancer stemness and chemotherapeutic sensitivity via triggering ferroptosis

Lv¹,

Wang²,

Hong-chao³

2023

Environmental Toxicology

View full text Add to dashboard Cite

The previous research has focused on the suppressive effects of Erianin on tumor progression, but its impact on cancer stemness has not been reported. This study aimed to investigate the effects of Erianin on lung cancer stemness. First, we screened various concentrations Erianin to ensure that it did not affect lung cancer cell viability. Subsequently, we found that Erianin significantly attenuated lung cancer stemness through various analyses, including qRT‐PCR, western blot, sphere‐formation, and ALDH activity detection. Furthermore, Erianin was shown to enhance chemosensitivity of lung cancer cells. Mechanistically, three inhibitors (cell apoptosis inhibitor, necrosis inhibitor, and ferroptosis inhibitor) were added into lung cancer cells with Erianin treatment, respectively, and we found that Erianin mainly suppressed lung cancer stemness through ferroptosis. Taken together, this study reveals that Erianin has the potential to suppress lung cancer stemness and could be a valuable chemotherapeutic enhancer for lung cancer.

show abstract

The effect and mechanism of erianin on the reversal of oxaliplatin resistance in human colon cancer cells

Cited by 15 publications

References 26 publications

MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen

MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen

Ultrasound-Assisted Extraction of Atractylodes chinensis (DC.) Koidz. Polysaccharides and the Synergistic Antigastric Cancer Effect in Combination with Oxaliplatin

Erianin suppressed lung cancer stemness and chemotherapeutic sensitivity via triggering ferroptosis

Contact Info

Product

Resources

About